<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">endoserg</journal-id><journal-title-group><journal-title xml:lang="ru">Эндокринная хирургия</journal-title><trans-title-group xml:lang="en"><trans-title>Endocrine Surgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2306-3513</issn><issn pub-type="epub">2310-3965</issn><publisher><publisher-name>Типография «Печатных дел Мастер»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/serg9572</article-id><article-id custom-type="elpub" pub-id-type="custom">endoserg-9572</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Обзоры литературы</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Review of literature</subject></subj-group></article-categories><title-group><article-title>Радионуклидная визуализация и терапия у пациентов с нейроэндокринными опухолями</article-title><trans-title-group xml:lang="en"><trans-title>Radionuclide imaging and therapy in patients with neuroendocrine tumors</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7548-9056</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баранова</surname><given-names>Ольга Дмитриевна</given-names></name><name name-style="western" xml:lang="en"><surname>Baranova</surname><given-names>Olga D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>клинический ординатор</p></bio><bio xml:lang="en"><p>MD</p></bio><email xlink:type="simple">olga.dm1091@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7721-634X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Румянцев</surname><given-names>Павел Олегович</given-names></name><name name-style="western" xml:lang="en"><surname>Roumiantsev</surname><given-names>Pavel O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., заведующий отделом радионуклидной диагностики и терапии</p></bio><bio xml:lang="en"><p>MD, PhD</p></bio><email xlink:type="simple">pavelrum@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3220-2438</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Слащук</surname><given-names>Константин Юрьевич</given-names></name><name name-style="western" xml:lang="en"><surname>Slashchuk</surname><given-names>Konstantin Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник отделения радионуклидной диагностики</p></bio><bio xml:lang="en"><p>MD</p></bio><email xlink:type="simple">slashuk911@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6272-9647</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>Леонид Олегович</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>Leonid O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., старший научный сотрудник абдоминального отделения</p></bio><bio xml:lang="en"><p>MD, PhD</p></bio><email xlink:type="simple">leonid_petrov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>&lt;p&gt;МНИОИ им. П.А. Герцена - филиал ФГБУ &amp;ldquo;Национальный медицинский исследовательский центр радиологии&amp;rdquo; Минздрава России&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;National Medical Research Radiological Center&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>&lt;p&gt;ФГБУ &amp;ldquo;Национальный медицинский исследовательский центр эндокринологии&amp;rdquo; Минздрава России&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;Endocrinology Research Centre&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>03</day><month>03</month><year>2018</year></pub-date><volume>11</volume><issue>4</issue><fpage>178</fpage><lpage>190</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Баранова О.Д., Румянцев П.О., Слащук К.Ю., Петров Л.О., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Баранова О.Д., Румянцев П.О., Слащук К.Ю., Петров Л.О.</copyright-holder><copyright-holder xml:lang="en">Baranova O.D., Roumiantsev P.O., Slashchuk K.Y., Petrov L.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surg-endojournals.ru/jour/article/view/9572">https://www.surg-endojournals.ru/jour/article/view/9572</self-uri><abstract><p>Нейроэндокринные опухоли представляют собой гетерогенную группу опухолей, возникающих из энтерохромаффинных клеток диффузной нейроэндокринной системы и встречающихся в 0,5% случаев всех новообразований. За последние годы отмечается значительный рост заболеваемости нейроэндокринными опухолями, что безусловно связано с усовершенствованием методов их диагностики. Однако, несмотря на значительные успехи в изучении биологических и молекулярных механизмов поведения данной группы заболеваний, формирование единого алгоритма диагностики и лечения нейроэндокринных опухолей остается затруднительным и по сей день. Лечение нейроэндокринных опухолей во многом зависит от их функционального статуса и стадии заболевания. Наиболее предпочтительным подходом в лечении локализованных форм нейроэндокринных опухолей остается хирургический. В то же время для больных с распространенными процессами, характеризующимися наличием отдаленных метастазов, на сегодняшний день доступен широкий спектр терапевтических стратегий. Среди них можно выделить контроль над синдромами, ассоциированными с гиперсекрецией тех или иных гормонов, выполнение циторедуктивных вмешательств, системную химиотерапию, применение аналогов соматостатина, а также радиотаргетную терапию. Однако алгоритм выбора того или иного терапевтического подхода в современной клинической практике у разнородной группы больных с нейроэндокринными опухолями требует дальнейшего обсуждения.</p></abstract><trans-abstract xml:lang="en"><p>Neuroendocrine tumors (NETs) are heterogeneous group of the tumors that arise from the enterochromaffin cells of the diffuse neuroendocrine system and occurr in 0.5% of all neoplasms. Recently there has been a significant increase in the incidence of neuroendocrine tumors, which is undoubtedly associated with the improvement of diagnostic methods. However, despite significant success in studying the biological and molecular mechanisms of its behavior, a single algorithm for the diagnosis and treatment of neuroendocrine tumors remains unclear today. Treatment of neuroendocrine tumors largely depends on their functional status and the stage of the disease. While the treatment of localized NETs is surgical resection, varieties of therapeutic options are available for patients with advanced NETs. These include medical control of excess hormone levels and associated symptoms, cytoreductive surgery for patients with advanced disease, systemic chemotherapy, somatostatin analogues, and peptide receptor-targeted radionuclide therapy. However, the right choice of the therapeutic approach in current clinical practice in heterogeneous group of patients with neuroendocrine tumors requires further discussion.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нейроэндокринные опухоли</kwd><kwd>радионуклидная диагностика</kwd><kwd>радиотаргетная терапия</kwd><kwd>аналоги соматостатина</kwd><kwd>октреотид</kwd><kwd>онкология</kwd><kwd>радиология</kwd></kwd-group><kwd-group xml:lang="en"><kwd>neuroendocrine tumors</kwd><kwd>radionuclide imaging</kwd><kwd>radiolabeled therapy</kwd><kwd>somatostatin analogues</kwd><kwd>octreotide</kwd><kwd>oncology</kwd><kwd>radiology</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Поисково-аналитическая работа проведена при поддержке ФГБУ “НМИЦ эндокринологии” Минздрава России и ОО “Ассоциация эндокринных хирургов”.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80 Suppl 1:3-7. doi: 10.1159/000080731.</mixed-citation><mixed-citation xml:lang="en">Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80 Suppl 1:3-7. doi: 10.1159/000080731.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61-72. doi: 10.1016/s1470-2045(07)70410-2.</mixed-citation><mixed-citation xml:lang="en">Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61-72. doi: 10.1016/s1470-2045(07)70410-2.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014(1):13-27. doi: 10.1196/annals.1294.002.</mixed-citation><mixed-citation xml:lang="en">Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014(1):13-27. doi: 10.1196/annals.1294.002.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072. doi: 10.1200/JCO.2007.15.4377.</mixed-citation><mixed-citation xml:lang="en">Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072. doi: 10.1200/JCO.2007.15.4377.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Solcia E, Klöppel G, Sobin LH. Histological Typing of Endocrine Tumors. Berlin Heidelberg: Springer; 2000. doi: 10.1007/978-3-642-59655-1.</mixed-citation><mixed-citation xml:lang="en">Solcia E, Klöppel G, Sobin LH. Histological Typing of Endocrine Tumors. Berlin Heidelberg: Springer; 2000. doi: 10.1007/978-3-642-59655-1.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45(2):234-243. doi: 10.1007/s00535-009-0194-8.</mixed-citation><mixed-citation xml:lang="en">Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45(2):234-243. doi: 10.1007/s00535-009-0194-8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794-1803. doi: 10.1093/annonc/mdq022.</mixed-citation><mixed-citation xml:lang="en">Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794-1803. doi: 10.1093/annonc/mdq022.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lepage C, Bouvier AM, Manfredi S, et al. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol. 2006;101(12):2826-2832. doi: 10.1111/j.1572-0241.2006.00854.x.</mixed-citation><mixed-citation xml:lang="en">Lepage C, Bouvier AM, Manfredi S, et al. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol. 2006;101(12):2826-2832. doi: 10.1111/j.1572-0241.2006.00854.x.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ploeckinger U, Kloeppel G, Wiedenmann B, et al. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology. 2009;90(4):349-363. doi: 10.1159/000242109.</mixed-citation><mixed-citation xml:lang="en">Ploeckinger U, Kloeppel G, Wiedenmann B, et al. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology. 2009;90(4):349-363. doi: 10.1159/000242109.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bergestuen DS, Aabakken L, Holm K, et al. Small intestinal neuroendocrine tumors: prognostic factors and survival. Scand J Gastroenterol. 2009;44(9):1084-1091. doi: 10.1080/00365520903082432.</mixed-citation><mixed-citation xml:lang="en">Bergestuen DS, Aabakken L, Holm K, et al. Small intestinal neuroendocrine tumors: prognostic factors and survival. Scand J Gastroenterol. 2009;44(9):1084-1091. doi: 10.1080/00365520903082432.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Williams E. The classification of carcinoid tumours. Lancet. 1963;281(7275):238-239. doi: 10.1016/s0140-6736(63)90951-6.</mixed-citation><mixed-citation xml:lang="en">Williams E. The classification of carcinoid tumours. Lancet. 1963;281(7275):238-239. doi: 10.1016/s0140-6736(63)90951-6.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO classification of tumors of the digestive system. Lyon: IARC; 2010. p. S13-S14.</mixed-citation><mixed-citation xml:lang="en">Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO classification of tumors of the digestive system. Lyon: IARC; 2010. p. S13-S14.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Van Eeden S, Quaedvlieg PF, Taal BG, et al. Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol. 2002;33(11):1126-1132. doi: 10.1053/hupa.2002.129204.</mixed-citation><mixed-citation xml:lang="en">Van Eeden S, Quaedvlieg PF, Taal BG, et al. Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol. 2002;33(11):1126-1132. doi: 10.1053/hupa.2002.129204.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kulke MH. Are neuroendocrine tumors going mainstream? J Clin Oncol. 2013;31(4):404-405. doi: 10.1200/jco.2012.47.3884.</mixed-citation><mixed-citation xml:lang="en">Kulke MH. Are neuroendocrine tumors going mainstream? J Clin Oncol. 2013;31(4):404-405. doi: 10.1200/jco.2012.47.3884.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152-160. doi: 10.1093/annonc/mds276.</mixed-citation><mixed-citation xml:lang="en">Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152-160. doi: 10.1093/annonc/mds276.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Velayoudom-Cephise FL, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20(5):649-657. doi: 10.1530/ERC-13-0027.</mixed-citation><mixed-citation xml:lang="en">Velayoudom-Cephise FL, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20(5):649-657. doi: 10.1530/ERC-13-0027.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015; 22(4):657-664. doi: 10.1530/ERC-15-0119.</mixed-citation><mixed-citation xml:lang="en">Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015; 22(4):657-664. doi: 10.1530/ERC-15-0119.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Basturk O, Yang Z, Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39(5):683-690. doi: 10.1097/PAS.0000000000000408.</mixed-citation><mixed-citation xml:lang="en">Basturk O, Yang Z, Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39(5):683-690. doi: 10.1097/PAS.0000000000000408.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192-1202. doi: 10.1097/PAS.0000000000000662.</mixed-citation><mixed-citation xml:lang="en">Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192-1202. doi: 10.1097/PAS.0000000000000662.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study. Gastroenterology. 1993; 104(4):994-1006. doi: 10.1016/0016-5085(93)90266-f.</mixed-citation><mixed-citation xml:lang="en">Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study. Gastroenterology. 1993; 104(4):994-1006. doi: 10.1016/0016-5085(93)90266-f.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Landerholm K, Falkmer S, Jarhult J. Epidemiology of small bowel carcinoids in a defined population. World J Surg. 2010;34(7):1500-1505. doi: 10.1007/s00268-010-0519-z.</mixed-citation><mixed-citation xml:lang="en">Landerholm K, Falkmer S, Jarhult J. Epidemiology of small bowel carcinoids in a defined population. World J Surg. 2010;34(7):1500-1505. doi: 10.1007/s00268-010-0519-z.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sitaraman SV, Goldfinger SE. Clinical characteristics of primary carcinoid tumors. In: Tannabe KK, Whitcomb DC, editors. UpToDate. Waltham: UpToDate; 2008.</mixed-citation><mixed-citation xml:lang="en">Sitaraman SV, Goldfinger SE. Clinical characteristics of primary carcinoid tumors. In: Tannabe KK, Whitcomb DC, editors. UpToDate. Waltham: UpToDate; 2008.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf P, Winhofer Y, Smajis S, et al. Clinical presentation in insulinoma predicts histopathological tumour characteristics. Clin Endocrinol (Oxf). 2015;83(1):67-71. doi: 10.1111/cen.12777.</mixed-citation><mixed-citation xml:lang="en">Wolf P, Winhofer Y, Smajis S, et al. Clinical presentation in insulinoma predicts histopathological tumour characteristics. Clin Endocrinol (Oxf). 2015;83(1):67-71. doi: 10.1111/cen.12777.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Yang RH, Chu YK. Zollinger-Ellison syndrome: Revelation of the gastrinoma triangle. Radiol Case Rep. 2015;10(1):827. doi: 10.2484/rcr.v10i1.827.</mixed-citation><mixed-citation xml:lang="en">Yang RH, Chu YK. Zollinger-Ellison syndrome: Revelation of the gastrinoma triangle. Radiol Case Rep. 2015;10(1):827. doi: 10.2484/rcr.v10i1.827.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Nikou GC, Toubanakis C, Nikolaou P, et al. Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005;52(66):1668-1676.</mixed-citation><mixed-citation xml:lang="en">Nikou GC, Toubanakis C, Nikolaou P, et al. Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005;52(66):1668-1676.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mortenson M, Bold RJ. Symptomatic pancreatic polypeptide-secreting tumor of the distal pancreas (PPoma). Int J Gastrointest Cancer. 2002;32(2-3):153-156. doi: 10.1385/ijgc:32:2-3:153.</mixed-citation><mixed-citation xml:lang="en">Mortenson M, Bold RJ. Symptomatic pancreatic polypeptide-secreting tumor of the distal pancreas (PPoma). Int J Gastrointest Cancer. 2002;32(2-3):153-156. doi: 10.1385/ijgc:32:2-3:153.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med. 1958;25(3):374-380. doi: 10.1016/0002-9343(58)90075-5.</mixed-citation><mixed-citation xml:lang="en">Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med. 1958;25(3):374-380. doi: 10.1016/0002-9343(58)90075-5.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Castro PG, de Leon AM, Trancon JG, et al. Glucagonoma syndrome: a case report. J Med Case Rep. 2011;5:402. doi: 10.1186/1752-1947-5-402.</mixed-citation><mixed-citation xml:lang="en">Castro PG, de Leon AM, Trancon JG, et al. Glucagonoma syndrome: a case report. J Med Case Rep. 2011;5:402. doi: 10.1186/1752-1947-5-402.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res. 1999;18(1):13-22.</mixed-citation><mixed-citation xml:lang="en">Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res. 1999;18(1):13-22.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Hajdu SI, Tang P. A note from history: the saga of carcinoid and oat-cell carcinoma. Ann Clin Lab Sci. 2008;38(4): 414-417.</mixed-citation><mixed-citation xml:lang="en">Hajdu SI, Tang P. A note from history: the saga of carcinoid and oat-cell carcinoma. Ann Clin Lab Sci. 2008;38(4): 414-417.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Masson P. Carcinoids (argentaffin-cell tumors) and nerve hyperplasia of the appendicular mucosa. Am J Pathol. 1928;4(3):181-212.</mixed-citation><mixed-citation xml:lang="en">Masson P. Carcinoids (argentaffin-cell tumors) and nerve hyperplasia of the appendicular mucosa. Am J Pathol. 1928;4(3):181-212.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Vinik AI, Silva MP, Woltering EA, et al. Biochemical testing for neuroendocrine tumors. Pancreas. 2009;38(8):876-889. doi: 10.1097/MPA.0b013e3181bc0e77.</mixed-citation><mixed-citation xml:lang="en">Vinik AI, Silva MP, Woltering EA, et al. Biochemical testing for neuroendocrine tumors. Pancreas. 2009;38(8):876-889. doi: 10.1097/MPA.0b013e3181bc0e77.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Modlin IM, Champaneria MC, Bornschein J, Kidd M. Evolution of the diffuse neuroendocrine system – clear cells and cloudy origins. Neuroendocrinology. 2006;84(2):69-82. doi: 10.1159/000096997.</mixed-citation><mixed-citation xml:lang="en">Modlin IM, Champaneria MC, Bornschein J, Kidd M. Evolution of the diffuse neuroendocrine system – clear cells and cloudy origins. Neuroendocrinology. 2006;84(2):69-82. doi: 10.1159/000096997.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18 Suppl 1:S17-25. doi: 10.1530/ERC-10-0280.</mixed-citation><mixed-citation xml:lang="en">Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18 Suppl 1:S17-25. doi: 10.1530/ERC-10-0280.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Kloppel G, Couvelard A, Perren A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology.2009;90(2): 162-166. doi: 10.1159/000182196.</mixed-citation><mixed-citation xml:lang="en">Kloppel G, Couvelard A, Perren A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology.2009;90(2): 162-166. doi: 10.1159/000182196.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435-e446. doi: 10.1016/s1470-2045(15)00186-2.</mixed-citation><mixed-citation xml:lang="en">Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435-e446. doi: 10.1016/s1470-2045(15)00186-2.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A – biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol. 2010;17(9):2427-2443. doi: 10.1245/s10434-010-1006-3.</mixed-citation><mixed-citation xml:lang="en">Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A – biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol. 2010;17(9):2427-2443. doi: 10.1245/s10434-010-1006-3.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Giusti M, Sidoti M, Augeri C, et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol. 2004;150(3):299-303. doi: 10.1530/eje.0.1500299.</mixed-citation><mixed-citation xml:lang="en">Giusti M, Sidoti M, Augeri C, et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol. 2004;150(3):299-303. doi: 10.1530/eje.0.1500299.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Yang X, Yang Y, Li Z, et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0124884. doi: 10.1371/journal.pone.0124884.</mixed-citation><mixed-citation xml:lang="en">Yang X, Yang Y, Li Z, et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0124884. doi: 10.1371/journal.pone.0124884.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer. 2007;14(2):473-482. doi: 10.1677/ERC-07-0001.</mixed-citation><mixed-citation xml:lang="en">Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer. 2007;14(2):473-482. doi: 10.1677/ERC-07-0001.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685-690. doi: 10.1023/a:1008215730767.</mixed-citation><mixed-citation xml:lang="en">Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685-690. doi: 10.1023/a:1008215730767.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas. 2010;39(6):753-766. doi: 10.1097/MPA.0b013e3181ebb2a5.</mixed-citation><mixed-citation xml:lang="en">Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas. 2010;39(6):753-766. doi: 10.1097/MPA.0b013e3181ebb2a5.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8-e21. doi: 10.1016/s1470-2045(13)70362-0.</mixed-citation><mixed-citation xml:lang="en">Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8-e21. doi: 10.1016/s1470-2045(13)70362-0.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85(6):295-330. doi: 10.1097/01.md.0000236956.74128.76.</mixed-citation><mixed-citation xml:lang="en">Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85(6):295-330. doi: 10.1097/01.md.0000236956.74128.76.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Massironi S, Conte D, Sciola V, et al. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol. 2010;105(9):2072-2078. doi: 10.1038/ajg.2010.154.</mixed-citation><mixed-citation xml:lang="en">Massironi S, Conte D, Sciola V, et al. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol. 2010;105(9):2072-2078. doi: 10.1038/ajg.2010.154.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Massironi S, Rossi RE, Casazza G, et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology. 2014;100(2-3):240-249. doi: 10.1159/000369818.</mixed-citation><mixed-citation xml:lang="en">Massironi S, Rossi RE, Casazza G, et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology. 2014;100(2-3):240-249. doi: 10.1159/000369818.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Rossi RE, Garcia-Hernandez J, Meyer T, et al. Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Ann Transl Med. 2015;3(9):118. doi: 10.3978/j.issn.2305-5839.2015.04.23.</mixed-citation><mixed-citation xml:lang="en">Rossi RE, Garcia-Hernandez J, Meyer T, et al. Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Ann Transl Med. 2015;3(9):118. doi: 10.3978/j.issn.2305-5839.2015.04.23.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557-577. doi: 10.1097/MPA.0b013e31828e34a4.</mixed-citation><mixed-citation xml:lang="en">Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557-577. doi: 10.1097/MPA.0b013e31828e34a4.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Ardill J. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer. 2003;10(4):459-462. doi: 10.1677/erc.0.0100459.</mixed-citation><mixed-citation xml:lang="en">Ardill J. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer. 2003;10(4):459-462. doi: 10.1677/erc.0.0100459.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Feldman JM, O&amp;apos;Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med. 1986;81(6):41-48. doi: 10.1016/0002-9343(86)90583-8.</mixed-citation><mixed-citation xml:lang="en">Feldman JM, O&amp;apos;Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med. 1986;81(6):41-48. doi: 10.1016/0002-9343(86)90583-8.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">O&amp;apos;Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009; 90(2):194-202. doi: 10.1159/000225948.</mixed-citation><mixed-citation xml:lang="en">O&amp;apos;Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009; 90(2):194-202. doi: 10.1159/000225948.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Kaltsas G, Rockall A, Papadogias D, et al. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol. 2004;151(1):15-27. doi: 10.1530/eje.0.1510015.</mixed-citation><mixed-citation xml:lang="en">Kaltsas G, Rockall A, Papadogias D, et al. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol. 2004;151(1):15-27. doi: 10.1530/eje.0.1510015.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Ricke J, Klose KJ, Mignon M, et al. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol. 2001;37(1):8-17. doi: 10.1016/s0720-048x(00)00187-x.</mixed-citation><mixed-citation xml:lang="en">Ricke J, Klose KJ, Mignon M, et al. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol. 2001;37(1):8-17. doi: 10.1016/s0720-048x(00)00187-x.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Binderup T, Knigge U, Mellon Mogensen A, et al. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology. 2008;87(4): 223-232. doi: 10.1159/000113128.</mixed-citation><mixed-citation xml:lang="en">Binderup T, Knigge U, Mellon Mogensen A, et al. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology. 2008;87(4): 223-232. doi: 10.1159/000113128.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Reubi J, Waser B, Schaer J-C, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28(7):836-846. doi: 10.1007/s002590100541.</mixed-citation><mixed-citation xml:lang="en">Reubi J, Waser B, Schaer J-C, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28(7):836-846. doi: 10.1007/s002590100541.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Oberg K, Jelic S, Group EGW. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii104-105. doi: 10.1093/annonc/mdn117.</mixed-citation><mixed-citation xml:lang="en">Oberg K, Jelic S, Group EGW. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii104-105. doi: 10.1093/annonc/mdn117.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Raderer M, Kurtaran A, Leimer M, et al. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol. 2000;18(6):1331-1336. doi: 10.1200/JCO.2000.18.6.1331.</mixed-citation><mixed-citation xml:lang="en">Raderer M, Kurtaran A, Leimer M, et al. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol. 2000;18(6):1331-1336. doi: 10.1200/JCO.2000.18.6.1331.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Lu SJ, Gnanasegaran G, Buscombe J, Navalkissoor S. Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature. Nucl Med Commun. 2013;34(2):98-107. doi: 10.1097/MNM.0b013e32835bd59d.</mixed-citation><mixed-citation xml:lang="en">Lu SJ, Gnanasegaran G, Buscombe J, Navalkissoor S. Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature. Nucl Med Commun. 2013;34(2):98-107. doi: 10.1097/MNM.0b013e32835bd59d.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Gabriel M, Muehllechner P, Decristoforo C, et al. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging. 2005;49(3):237-244.</mixed-citation><mixed-citation xml:lang="en">Gabriel M, Muehllechner P, Decristoforo C, et al. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging. 2005;49(3):237-244.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years&amp;apos; experience. Eur J Nucl Med Mol Imaging. 2006;33(10):1123-1133. doi: 10.1007/s00259-006-0113-7.</mixed-citation><mixed-citation xml:lang="en">Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years&amp;apos; experience. Eur J Nucl Med Mol Imaging. 2006;33(10):1123-1133. doi: 10.1007/s00259-006-0113-7.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44(5):708-716.</mixed-citation><mixed-citation xml:lang="en">Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44(5):708-716.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Reubi JC, Schär J-C, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging. 2000;27(3): 273-282. doi: 10.1007/s002590050034.</mixed-citation><mixed-citation xml:lang="en">Reubi JC, Schär J-C, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging. 2000;27(3): 273-282. doi: 10.1007/s002590050034.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34(7):982-993. doi: 10.1007/s00259-006-0317-x.</mixed-citation><mixed-citation xml:lang="en">Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34(7):982-993. doi: 10.1007/s00259-006-0317-x.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Besig S, Voland P, Baur DM, et al. Vascular endothelial growth factors, angiogenesis, and survival in human ileal enterochromaffin cell carcinoids. Neuroendocrinology. 2009;90(4): 402-415. doi: 10.1159/000245900.</mixed-citation><mixed-citation xml:lang="en">Besig S, Voland P, Baur DM, et al. Vascular endothelial growth factors, angiogenesis, and survival in human ileal enterochromaffin cell carcinoids. Neuroendocrinology. 2009;90(4): 402-415. doi: 10.1159/000245900.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Voland P, Besig S, Rad R, et al. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival. Neuroendocrinology. 2009;89(1):66-78. doi: 10.1159/000151482.</mixed-citation><mixed-citation xml:lang="en">Voland P, Besig S, Rad R, et al. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival. Neuroendocrinology. 2009;89(1):66-78. doi: 10.1159/000151482.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Hassan MM, Phan A, Li D, et al. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev. 2008;17(4):959-965. doi: 10.1158/1055-9965.EPI-07-0750.</mixed-citation><mixed-citation xml:lang="en">Hassan MM, Phan A, Li D, et al. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev. 2008;17(4):959-965. doi: 10.1158/1055-9965.EPI-07-0750.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Hemminki K, Li X. Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer. 2001;94(3):444-448. doi: 10.1002/ijc.1473.</mixed-citation><mixed-citation xml:lang="en">Hemminki K, Li X. Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer. 2001;94(3):444-448. doi: 10.1002/ijc.1473.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Jarhult J, Landerholm K, Falkmer S, et al. First report on metastasizing small bowel carcinoids in first-degree relatives in three generations. Neuroendocrinology. 2010; 91(4):318-323. doi: 10.1159/000299790.</mixed-citation><mixed-citation xml:lang="en">Jarhult J, Landerholm K, Falkmer S, et al. First report on metastasizing small bowel carcinoids in first-degree relatives in three generations. Neuroendocrinology. 2010; 91(4):318-323. doi: 10.1159/000299790.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Tonnies H, Toliat MR, Ramel C, et al. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut. 2001;48(4):536-541. doi: 10.1136/gut.48.4.536.</mixed-citation><mixed-citation xml:lang="en">Tonnies H, Toliat MR, Ramel C, et al. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut. 2001;48(4):536-541. doi: 10.1136/gut.48.4.536.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117(15): 3332-3341. doi: 10.1002/cncr.25855.</mixed-citation><mixed-citation xml:lang="en">Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117(15): 3332-3341. doi: 10.1002/cncr.25855.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Schindl M, Kaczirek K, Passler C, et al. Treatment of small intestinal neuroendocrine tumors: is an extended multimodal approach justified? World J Surg. 2002;26(8):976-984. doi: 10.1007/s00268-002-6628-6.</mixed-citation><mixed-citation xml:lang="en">Schindl M, Kaczirek K, Passler C, et al. Treatment of small intestinal neuroendocrine tumors: is an extended multimodal approach justified? World J Surg. 2002;26(8):976-984. doi: 10.1007/s00268-002-6628-6.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757-762. doi: 10.1007/s00428-007-0452-1.</mixed-citation><mixed-citation xml:lang="en">Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757-762. doi: 10.1007/s00428-007-0452-1.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469-1492. doi: 10.1053/j.gastro.2008.05.047.</mixed-citation><mixed-citation xml:lang="en">Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469-1492. doi: 10.1053/j.gastro.2008.05.047.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Saxena A, Chua TC, Chu F, et al. Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation. Am J Clin Oncol. 2012; 35(5):439-445. doi: 10.1097/COC.0b013e31821bc8dd.</mixed-citation><mixed-citation xml:lang="en">Saxena A, Chua TC, Chu F, et al. Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation. Am J Clin Oncol. 2012; 35(5):439-445. doi: 10.1097/COC.0b013e31821bc8dd.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Birnbaum DJ, Turrini O, Vigano L, et al. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Ann Surg Oncol. 2015;22(3):1000-1007. doi: 10.1245/s10434-014-4016-8.</mixed-citation><mixed-citation xml:lang="en">Birnbaum DJ, Turrini O, Vigano L, et al. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Ann Surg Oncol. 2015;22(3):1000-1007. doi: 10.1245/s10434-014-4016-8.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan CH, Wang J, Xiu DR, et al. Meta-analysis of liver resection versus nonsurgical treatments for pancreatic neuroendocrine tumors with liver metastases. Ann Surg Oncol. 2016;23(1):244-249. doi: 10.1245/s10434-015-4654-5.</mixed-citation><mixed-citation xml:lang="en">Yuan CH, Wang J, Xiu DR, et al. Meta-analysis of liver resection versus nonsurgical treatments for pancreatic neuroendocrine tumors with liver metastases. Ann Surg Oncol. 2016;23(1):244-249. doi: 10.1245/s10434-015-4654-5.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Møller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta. 2003;1616(1):1-84. doi: 10.1016/s0005-2736(03)00235-9.</mixed-citation><mixed-citation xml:lang="en">Møller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta. 2003;1616(1):1-84. doi: 10.1016/s0005-2736(03)00235-9.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J ClinOncol. 2009;27(28):4656-4663. doi: 10.1200/JCO.2009.22.8510.</mixed-citation><mixed-citation xml:lang="en">Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J ClinOncol. 2009;27(28):4656-4663. doi: 10.1200/JCO.2009.22.8510.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-293. doi: 10.1016/j.cell.2012.03.017.</mixed-citation><mixed-citation xml:lang="en">Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-293. doi: 10.1016/j.cell.2012.03.017.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Oberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21 Suppl 7:vii72-80. doi: 10.1093/annonc/mdq290.</mixed-citation><mixed-citation xml:lang="en">Oberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21 Suppl 7:vii72-80. doi: 10.1093/annonc/mdq290.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514-523. doi: 10.1056/NEJMoa1009290.</mixed-citation><mixed-citation xml:lang="en">Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514-523. doi: 10.1056/NEJMoa1009290.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022): 968-977. doi: 10.1016/s0140-6736(15)00817-x.</mixed-citation><mixed-citation xml:lang="en">Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022): 968-977. doi: 10.1016/s0140-6736(15)00817-x.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-513. doi: 10.1056/NEJMoa1003825.</mixed-citation><mixed-citation xml:lang="en">Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-513. doi: 10.1056/NEJMoa1003825.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Phan AT, Halperin DM, Chan JA, et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015;16(6):695-703. doi: 10.1016/s1470-2045(15)70136-1.</mixed-citation><mixed-citation xml:lang="en">Phan AT, Halperin DM, Chan JA, et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015;16(6):695-703. doi: 10.1016/s1470-2045(15)70136-1.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Yao JC, Guthrie KA, Moran C, et al. Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol. 2017;35(15):1695-1703. doi: 10.1200/JCO.2016.70.4072.</mixed-citation><mixed-citation xml:lang="en">Yao JC, Guthrie KA, Moran C, et al. Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol. 2017;35(15):1695-1703. doi: 10.1200/JCO.2016.70.4072.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135. doi: 10.1056/NEJMoa1607427.</mixed-citation><mixed-citation xml:lang="en">Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135. doi: 10.1056/NEJMoa1607427.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016;103(2):186-194. doi: 10.1159/000443172.</mixed-citation><mixed-citation xml:lang="en">Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016;103(2):186-194. doi: 10.1159/000443172.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Moertel CG, Kvols LK, O&amp;apos;Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68(2): 227-232. doi: 10.1002/1097-0142(19910715)68:2&lt;227::aid-cncr2820680202&gt;3.0.co;2-i.</mixed-citation><mixed-citation xml:lang="en">Moertel CG, Kvols LK, O&amp;apos;Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68(2): 227-232. doi: 10.1002/1097-0142(19910715)68:2&lt;227::aid-cncr2820680202&gt;3.0.co;2-i.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Hentic O, Hammel P, Couvelard A, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012;19(6): 751-757. doi: 10.1530/ERC-12-0002.</mixed-citation><mixed-citation xml:lang="en">Hentic O, Hammel P, Couvelard A, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012;19(6): 751-757. doi: 10.1530/ERC-12-0002.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Hadoux J, Malka D, Planchard D, et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer. 2015;22(3):289-298. doi: 10.1530/ERC-15-0075.</mixed-citation><mixed-citation xml:lang="en">Hadoux J, Malka D, Planchard D, et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer. 2015;22(3):289-298. doi: 10.1530/ERC-15-0075.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Pavel M, O&amp;apos;Toole D, Costa F, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172-185. doi: 10.1159/000443167.</mixed-citation><mixed-citation xml:lang="en">Pavel M, O&amp;apos;Toole D, Costa F, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172-185. doi: 10.1159/000443167.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Ezziddin S, Opitz M, Attassi M, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011;38(3):459-466. doi: 10.1007/s00259-010-1610-2.</mixed-citation><mixed-citation xml:lang="en">Ezziddin S, Opitz M, Attassi M, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011;38(3):459-466. doi: 10.1007/s00259-010-1610-2.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
